Please provide your email address to receive an email when new articles are posted on . DENVER — Early initiation of treatment with ofatumumab showed sustained benefit to those with treatment-naïve ...

Ofatumumab is more effective than teriflunomide for relapsing multiple sclerosis across subgroups. HealthDay News — For patients with relapsing multiple sclerosis (RMS), ofatumumab is more effective ...

The monoclonal antibody ofatumumab appears to be more effective in achieving a disease-free state in relapsing-remitting multiple sclerosis (RRMS) than the immunomodulatory drug teriflunomide, across ...

MINNEAPOLIS – For people with relapsing-remitting multiple sclerosis (MS), a new study has found that the drug ofatumumab is more effective than teriflunomide at helping people across racial and ...

COPENHAGEN (Reuters) - Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its sclerosis drug candidate ofatumumab. In a randomized study of 232 patients with ...

A new monoclonal antibody treatment called Kesimpta (ofatumumab) appears to improve on an older drug in pushing multiple sclerosis (MS) into remission, a new trial shows. Funded by Kesimpta's maker, ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways MS medications can help slow the disease and manage symptoms.